For patients with stable COPD, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend bronchodilator maintenance therapy with an inhaled long-acting β2-agonist (LABA e.g., salmeterol, formoterol, or vilanterol) or a long-acting muscarinic antagonist (LAMA e.g., umeclidinium or tiotropium). COPD therefore represents a major public health challenge in the US.Īlthough COPD is an incurable and irreversible disease, pharmacological treatments are used to manage symptoms, reduce the frequency and severity of exacerbations, increase exercise capacity, and improve quality of life. This figure includes direct costs relating to COPD diagnosis, treatment, and hospitalization, and indirect costs (for example, missed days of work) resulting from disease morbidity and mortality. The annual economic burden of COPD in the US was estimated to be US$50 billion in 2010. In 2018, chronic lower respiratory diseases (including COPD) were the fourth most common cause of death in the US, following heart disease, cancer, and unintentional injuries. ĬOPD was reported to affect 6.4% of adults in the US in 2013, which corresponds to approximately 15.7 million cases. Comorbidities frequently found among COPD patients include cardiovascular disease, osteoporosis, arthritis, asthma, diabetes/metabolic syndrome, and depression. Many patients with COPD also suffer from comorbidities, which can complicate disease management and contribute to morbidity and mortality. COPD symptoms progressively worsen over time and have a negative impact on patient quality of life and disease prognosis. COPD symptoms include dyspnea, wheezing, chronic cough, sputum production, and limited exercise capacity. The results of this study suggest that SITT with FF/UMEC/VI is used most often in accordance with treatment guidelines from the Global Initiative for Chronic Obstructive Lung Disease.Ĭhronic obstructive pulmonary disease (COPD) is a progressive respiratory condition that is characterized by chronic inflammation of the airways and persistent airflow limitation. The results of this study suggest that SITT with FF/UMEC/VI is frequently initiated as a step-up treatment in patients with COPD who have persistent symptoms or a history of exacerbations, despite dual maintenance therapy. This study aimed to assess the characteristics of patients initiating SITT with FF/UMEC/VI. The baseline demographic and clinical characteristics of patients initiating multiple-inhaler triple therapy have previously been assessed however, the characteristics of patients initiating SITT remain unknown. Until recently, triple therapy was delivered via multiple inhalers in 2017, single-inhaler triple therapy (SITT) with fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) was approved for the long-term maintenance treatment of patients with moderate-to-severe COPD in the United States. Triple therapy is recommended for patients with chronic obstructive pulmonary disease (COPD), who remain symptomatic or at risk of exacerbation despite dual therapy. In this population of COPD patients, triple therapy was frequently initiated after previous maintenance medication use or an exacerbation, in line with treatment guideline recommendations. In addition, 41.2% of FF/UMEC/VI users received overlapping ICS/LAMA/LABA, 20.3% received ICS/LABA, and 9.7% received LAMA/LABA. Prior to initiating triple therapy, the majority of FF/UMEC/VI (89.1%) and MITT (93.8%) users experienced a moderate or severe exacerbation or used a COPD maintenance therapy during the baseline period. Mean (standard deviation) patient age was 72.2 (8.6) years in FF/UMEC/VI users and 70.7 (9.7) years in MITT users. The study population included 3933 FF/UMEC/VI users and 18,244 MITT users. Patient characteristics, comorbidities, COPD medication use, exacerbations, and eosinophil counts were assessed in the 12-month baseline period prior to initiation of FF/UMEC/VI triple therapy or MITT. Patients who initiated FF/UMEC/VI triple therapy or MITT (consisting of a long-acting muscarinic antagonist, long-acting β2-agonist , and inhaled corticosteroid ) between October 2017 and September 2018, were enrolled in commercial or Medicare Advantage Prescription Drug plans, were aged > 40 years, and had a COPD diagnosis were eligible. This was a retrospective study using the Optum Clinformatics ® Data Mart. This study assessed patient characteristics, exacerbation, and medication history in patients with COPD before the initiation of FF/UMEC/VI or multiple-inhaler triple therapy (MITT). Patient characteristics and treatment patterns prior to initiating FF/UMEC/VI are currently unknown. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy was approved by the United States Food and Drug Administration in 2017 as a maintenance therapy for chronic obstructive pulmonary disease (COPD).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |